Treating seasonal influenza genetically modified cattle to help produce broad-spectrum antibody therapies

Today, SAB Biotherapeutics announced that its polyclonal antibody therapy SAB-176 for the treatment of seasonal influenza has reached its primary endpoint in a Phase 2a clinical trial for the treatment of seasonal influenza

Influenza virus infection is one of the most common infectious diseases, causing 2.

SAB-176 is a fully humanized broad-spectrum neutralizing polyclonal antibody

SAB Biotherapeutics' technology platform uses genetically engineered cattle to produce a large number of fully humanized antibodies.

In this randomized, double-blind, placebo-controlled Phase 2a clinical trial, healthy volunteers received SAB-176 or placebo and were nasally inoculated with H1N1 influenza virus.

In addition, in patients with symptoms, SAB-176 significantly reduced the clinical symptoms of influenza compared with placebo (one-sided p=0.

In this study, SAB-176 showed good safety and tolerability, no serious adverse events related to it were observed, and most of the adverse events were mild or moderate

Reference materials:

[1] SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus.

(The original text has been deleted)